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findings of the studies listed above in quantitative terms, it is
conservative to estimate that approximately half of all infarcts
without Q waves will manifest Q-wave–equivalent distortions of
depolarization. . . . The only scientifically valid basis for compari-
son would be ‘depolarization abnormality’ versus ‘repolarization
abnormality only.’ Thus, even if only a third of the NQWMI in
fact belong in the QWMI category—a modest assumption—the
differences alleged in this study could be markedly altered” (4).
Every pathologic study in the last 20 or more years has
demonstrated that the pathology of the two types of infarct is
identical (5,6). Most recently Wu et al. (7) published a study
correlating ECG with pathology; like all others, the researchers
found that nontransmural infarcts generated Q waves 50% of the
time. It is difficult to imagine the NQWMI to be a “distinct
pathophysiologic entity” when the cellular pathology is exactly the
same as the QWMI.
The investigators (1) erroneously reported that Edlavitch et al.
(8) provided data that support the conclusion of the present study
that an increase in the incidence of NQWMI and QWMI
occurred over a period of time. In that study, which preceded the
thrombolytic area and extended from 1970 to 1980, the attack rate
for QWMI did not change significantly between 1970 and 1980,
but the attack rate for NQWMI decreased significantly during this
same period.
Finally, the preoccupation with Q-wave versus NQWMI
should be abandoned in favor of truly significant observations that
have a well-documented bearing on acute as well as long-term
prognosis, such as evaluation of infarct size, left ventricular ejection
fraction, New York Heart Association functional class, coronary
anatomy and symptoms. These observations will be able to guide
the cardiologist in the choice of therapy and prognosis. The Q
versus non-Q distinction contributes nothing of pragmatic thera-
peutic significance, as is demonstrated by the fact that patients
with NQWMI randomly assigned to an invasive or noninvasive or
conservative management resulted in similar outcome (9).
Brendan P. Phibbs, MD
Chief of Cardiology
Kino Community Hospital
2800 East Ajo Way
Tucson, Arizona 85713
Frank I. Marcus, MD
PII S0735-1097(01)01754-5
REFERENCES
1. Furman MI, Dauerman DL, Goldberg RJ, Yazbeski J, Lessard D, Gore
JM. Twenty-two-year (1975–1997) trends in the incidence, in-hospital
and case fatality rates from initial Q wave and non-Q wave myocardial
infarction. A multi-hospital community-wide perspective. J Am Coll
Cardiol 2001;37:1571–80.
2. Kleiger RE, Boden WE, Schechtman KB, et al., and the Diltiazem
Reinfarction Study Group. Frequency and significance of late evolution
of Q waves in patients with initial non-Q wave myocardial infarction.
Am J Cardiol 1990;65:23–7.
3. The Joint European Society of Cardiology/American College of Car-
diology Committee for the Redefinition of Myocardial Infarction. A
consensus document. J Am Coll Cardiol 2000;36:959–67.
4. Phibbs B, Marcus FL, Marriott HJC, Moss A, Spodick D. Q-wave
versus non-Q wave myocardial infarction: a meaningless distinction.
J Am Coll Cardiol 1999;33:576–82.
5. Phibbs B. “Transmural” versus “subendocardial” myocardial infarction:
an electrocardiographic myth. J Am Coll Cardial 1983;1:561–4.
6. Spodick D. Q-wave infarction versus S-T infarction: nonspecificity of
electrocardiographic criteria for differentiating transmural and non-
transmural lesions. Am J Cardiol 1983;51:914–7.
7. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ.
Visualization of presence, location and transmural extent of healed Q
and non-Q myocardial infarcts. Lancet 2001;357:21–8.
8. Edlavitch SA, Crow R, Burke GL, Baxter J. Secular trends in Q wave
and non-Q wave acute myocardial infarction. The Minnesota Heart
Survey. Circulation 1991;83:492–503.
9. Boden WE, O’Rourke RA, Crawford MH, et al. for the Veterans
Affairs non-Q-Wave Infarction Strategies in Hospital (VANQWISH)
trial investigators. Outcomes in patients with acute non-Q wave
myocardial infarction randomly assigned to an invasive as compared
with a non-invasive strategy. N Engl J Med 1998;338:1785–92.
REPLY
In their letter to the editor, Phibbs and Marcus essentially reiterate
what they wrote in their 1999 editorial (1) in the Journal of the
American College of Cardiology. Indeed, the research that resulted in
our article (2) was initiated as a result of the publication of the
editorial. We agree that classifying myocardial infarction (MI) into
Q-wave and non–Q-wave is not ideal and should be replaced with
ST-segment elevation MI and non–ST-segment elevation MI.
However, because the distinction between Q-wave and non–Q-
wave MI has been standard in the literature, it is necessary to use
it to ascertain past trends in incidence and short-term and
long-term mortality rates. We agree with Phibbs and Marcus’s
contention that electrocardiograph (ECG) changes in MI correlate
poorly with the extent of transmural myocardial necrosis. We also
agree that the definition of Q-wave we used is an “older”
definition. However, as our initial study period began in 1975, we
are forced to use the original definition of Q-wave MI. We
consider that the fact that our study originated in 1975, and that
our definition was consistent over 22 years, is one of our study’s
strengths.
We disagree with Phibbs and Marcus that the pathology of
Q-wave and non–Q-wave MI is the same. The essential role of the
extent and pathology of coronary atherosclerosis is a critical
determinant as to why certain patients develop unstable angina,
non–Q-wave MI, or Q-wave MI. The simple fact remains that
patients with initial non–Q-wave MI, including some patients
with transmural infarction and others with “Q-wave equivalents,”
have consistently over time shown a worse long-term prognosis
than survivors of initial Q-wave MI and until most recently no
change in hospital mortality. These distinctions are of paramount
importance and strongly suggest that separate pathophysiologic
processes may be partially responsible for these differences in
outcomes.
The TACTICS-TIMI study (3) demonstrated that, in patients
with unstable angina and non–ST-segment elevation MI receiving
a glycoprotein IIb-IIIa antagonist, those who underwent an early
invasive strategy, as compared with those who underwent an early
conservative strategy, had a significant decrease in adverse cardiac
events. The fact that, until recently, there has been no proven
effective therapy for the reduction of mortality in patients with
non–Q-wave MI further suggests that the pathophysiologic pro-
cesses leading to non–Q-wave MI are distinct from Q-wave MI.
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A Stent With Extent—Fiction or Prophecy?
Kobayashi et al. (1) demonstrated the in vivo mechanical proper-
ties of the Radius stent, a self-expanding coronary stent. They
studied the subsequent vessel response over time in a group of 62
patients randomized to either the Radius self-expanding stent or
the Palmaz-Schatz balloon-expandable stent.
Using intravascular ultrasound studies after stent deployment
and at six-month follow-up, the researchers concluded that the
Radius stents continued to enlarge during the follow-up period
(increased 24%) while the Palmaz-Schatz stents had remained
unchanged. The expansion was accompanied by a greater amount
of neointima than the Palmaz-Schatz stents (3.0  1.7 mm2 vs.
1.9  1.2 mm2), resulting in similar late lumen loss in both
configurations.
Our group has been intensively involved in the development of
self-expanding stents, demonstrating the concept of long-term
expansion in animal and clinical models (2–4). In a study pub-
lished in 1999 we reported the first human experience with the
nitinol self-expanding coil stent (5). In a series of 64 patients, we
provided clinical and angiographic data on the effect of self-
expansion during implantation and follow-up. Balloon angioplasty
increased the minimal lumen diameter (MLD) from 1.07 
0.73 mm to 2.24  0.57 mm; stent deployment further increased
the diameter to 2.63 0.48 mm, and within-stent balloon dilation
to 2.96  0.62 mm. Angiographic follow-up showed that the
MLD was 2.15  0.80 mm (late lumen loss of 0.81  0.69 mm),
and the mean stent diameter expanded to 3.58  0.48 mm
(self-expanding late stent gain of 0.62  0.55 mm). The extent of
this expansion was inversely related to the late lumen loss. Several
patients presented a positive remodeling (i.e., their MLD in-
creased at follow-up). A one year, 51 (80%) of 64 patients were
event free.
The self-expanding nitinol stent exerts its acute effect on MLD
through its intrinsic radial force aided by balloon expansion.
Self-expanding stents do not reach their nominal diameter at
implantation. The stent continues to expand until it reaches its
nominal diameter over the follow-up period. The extent of this
expansion is inversely related to the late lumen loss, which may be
due to the continuous injury stimulus by the continued expansion.
The balance between continued expansion and neointimal prolif-
eration determines the late lumen loss, which is the critical
parameter determining long-term stent performance. Kobayashi et
al. (1) do not answer the main question arising from their excellent
study. What is the place of self-expanding stents today, at the start
of the era of the coated balloon-expandable stent?
Based on our results and those of the present study, despite the
promising theoretical benefits of these continued expanding stents
and because of the exaggerated neointimal proliferation, there is no
net late gain compared to balloon-expandable stents. Methods to
reduce intimal proliferation after implantation of self-expanding
stents may include optimal size selection, acute implant method-
ology with respect to pre- and post-stent dilation and in situ
pharmacologic methods to reduce this proliferation. Therefore, the
possible success of such stents in coronary artery disease will
critically depend upon our ability to limit the proliferative response
to that stent. It is timely that a study combining an effective
antiproliferative coating and a self-expanding stent will determine
the role of long-term stent expansion, without the counterproduc-
tive intimal response.
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